Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Total Non-Current Liabilities (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Total Non-Current Liabilities data on record, last reported at $559500.0 in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 4.91% year-over-year to $559500.0; the TTM value through Sep 2025 reached $559500.0, up 4.91%, while the annual FY2024 figure was $528125.0, 31.27% down from the prior year.
  • Total Non-Current Liabilities reached $559500.0 in Q3 2025 per COEP's latest filing, down from $636124.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $4.1 million in Q3 2022 and bottomed at $337999.0 in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $1.4 million, with a median of $768429.0 recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 86.89% in 2023, then grew 4.91% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.6 million in 2021, then fell by 21.83% to $1.3 million in 2022, then plummeted by 40.42% to $768429.0 in 2023, then plummeted by 31.27% to $528125.0 in 2024, then increased by 5.94% to $559500.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $559500.0 in Q3 2025, $636124.0 in Q2 2025, and $337999.0 in Q1 2025.